You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Antibody targeting of ADAM for treatment of triple negative breast cancer

    SBC: ADECTO PHARMACEUTICALS, INC.            Topic: NCI

    DESCRIPTION provided by applicant Triple negative breast cancers TNBCs account for of breast cancer deaths and lack targeted therapies Drs Sonenshein Mineva and Romagnoli and their co workers recently identified the non essential cell surface protein ADAM A Disintegrin and Metalloprotease as a pivotal promoter of breast tumor growth and metastasis and validated it as a target o ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Small molecule inhibitors targeting oncogenic drivers of hepatocellular carcinoma

    SBC: L2 DIAGNOSTICS LLC            Topic: 102

    DESCRIPTION provided by applicant Hepatocellular carcinoma HCC is the most prevalent cancer in human population and will lead to over deaths in the United States this year alone However the molecular mechanisms driving hepatocellular carcinoma HCC growth and metastasis remain elusive and there is a huge unmet medical need to find new therapeutic targets We performed an unbiased ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Lipidated Stable BAM8-22 Offers a Promising Therapeutic for Neuropathic Pain

    SBC: On Target Therapeutics, LLC            Topic: 106

    DESCRIPTION provided by applicant Neuropathic pain is a serious health problem that affects millions of people worldwide and occurs in as much as of the general population The management of neuropathic pain in patients is complex with an estimated of individuals refractory to existing analgesic therapies The aging population the diabetes epidemic and the significant cohorts of can ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Simultaneous kinetic analyses of neuronal connectivities

    SBC: CIENCIA INC            Topic: 101

    DESCRIPTION provided by applicant Aberrant neuronal connectivity is associated with a number of neuropathological and neuropsychiatric diseases disorders Inefficient developmental connectivity misdirected connectivity or disrupted and degenerated connectivity can account for losses of normal neuronal communication and subsequent losses of mental or physical health Altered expression of axon ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Non-Invasive, Highly Specific Detection of Oxytocin in Biological Fluids

    SBC: GINER INC            Topic: NICHD

    DESCRIPTION provided by applicant Non Invasive Highly Specific Detection of Oxytocin in Biological Fluids Oxytocin a neuropeptide hormone plays an important role in a variety of complex social behaviors including affiliation sexual behavior and aggression It is best known for its role to facilitate the birth process through induction of myometrial muscle contractions However recent studi ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Rapid Detection of Multiple Drug resistant TB from Sputum

    SBC: TANGEN BIOSCIENCES, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Tuberculosis TB is a leading cause of mortality from an infectious disease in the world second only to HIV AIDS The WHO reports that in there were M deaths from TB When a case of TB does not respond to two or more of the first line drugs available the infection is considered to be multidrug resistant MDR TB The rising incidence of MDR TB is lea ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Optimization of a mucosal RSV vaccine

    SBC: Biomedical Research Models, Inc.            Topic: NIAID

    Abstract Human respiratory syncytial virus RSV is a highly infectious member of the paramyxovirus family causing upper and lower respiratory tract infections RSV is the leading cause of pulmonary disease of the lower respiratory tract bronchiolitis pneumonia and respiratory failure in infants due to virus induced airway damage and complex inflammatory processes and responsible for an estima ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Engineered bacteriophage as a platform to deliver nucleic acid based therapeutics to bacteria to disperse biofilms in implant-associated infections such as prosthetic joint infections

    SBC: EnBiotix, Inc.            Topic: NIAID

    Abstract Bacteriophages are viruses that specifically and solely infect bacteria and are a natural platform delivery system of genetic information encoded by nucleic acids to bacteria Lytic bacteriophages do not integrate their DNA into the bacterial chromosome but replicate independently and ultimately kill their host bacteria In the early andapos s bacteriophages were used to fight inf ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Evaluating the impact of novel inhibitors of nuclear pore export in SLE

    SBC: KARYOPHARM THERAPEUTICS INC.            Topic: NIAID

    DESCRIPTION provided by applicant Systemic lupus erythematosus SLE is a complex autoimmune disease with a broad spectrum of clinical manifestations affecting several organs and associated with dysregulation of the immune system This disease affects millions of individuals with women and underserved minorities disproportionately burdened It is associated with significant morbidity and morta ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Rapid Phenotypic Antibiotic Susceptibility Testing

    SBC: BIOSENSE TECHNOLOGIES, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Infectious disease has now entered a post antibiotic era where multi drug resistance is increasingly common There is an immediate need for new diagnostics that can determine the susceptibility of pathogenic bacteria to antibiotics rapidly and accelerate the administration of targeted therapy for optimal patient outcomes BioSense Technologies proposes the deve ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government